This approach identifies useful molecular markers to assess the benefit of neuroprotective treatment approaches, at a time when the utilization of ATXN2-ASOs for the treatment of SCA2 and ALS in clinical trials is imminent. This evidence concerns the gene ATXN2 and amyotrophic lateral sclerosis.